Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Technologies, Heat Biologics, and Inovio Pharmaceuticals Are Cratering Today

By George Budwell – Aug 11, 2020 at 11:27AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Russia's surprise vaccine announcement isn't sitting well with shareholders of Dynavax, Heat Biologics, or Inovio Pharmaceuticals.

What happened

Shares of the COVID-19 vaccine companies Dynavax Technologies (DVAX 0.00%), Heat Biologics (HTBX 0.00%), and Inovio Pharmaceuticals (INO -3.39%) all opened Tuesday's trading session down by more than 10%. While company specifics vary, the central theme behind these downward moves appears to be the news that Russia approved the world's first COVID-19 vaccine, dubbed Sputnik-V, today.

In response to this unexpected news, Heat Biologics' shares are currently off by 11.8%, Dynavax's stock is down by 9.7%, and Inovio Pharmaceuticals' equity is in the red by a noteworthy 21% as of 10:13 a.m. EDT Tuesday.

A vial and syringe set against a blue background.

Image Source: Getty Images.

So what

Dynavax, Heat Biologics, and Inovio Pharmaceuticals were all hoping to become key players in the COVID-19 vaccine landscape. Investors, however, appear to be taking this Russian vaccine news to heart, perhaps because President Putin announced that one of his daughters received the vaccine.

Putin's claims that the vaccine is "quite effective" and that it forms "stable immunity" are questionable at best. The fact of the matter is that this vaccine did not undergo the rigorous clinical testing -- or regulatory review -- necessary to support such a bold statement in regard to its efficacy or safety. Underscoring this point, CNN reported that Russia did not release any actual data backing up these claims.

Now what

The big picture is that there's little chance that this Russian vaccine candidate will usurp any of the COVID-19 treatments in development in Western nations, such as the United States or United Kingdom. This seems to be a political move to position Russia as a scientific powerhouse. Nothing more.

As such, these double-digit moves in the shares of Dynavax, Heat Biologics, and Inovio Pharmaceuticals, in reaction to this Russian vaccine news, are arguably unjustified. Therefore, bargain hunters might want to take advantage of this weakness in each of these biotech stocks today.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
$10.24 (0.00%) $0.00
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$1.71 (-3.39%) $0.06
Heat Biologics, Inc. Stock Quote
Heat Biologics, Inc.
$1.79 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.